Welcome!

News Feed Item

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
http://www.reportlinker.com/p02013603/PharmaSphere-Pharmaceutical-and-Healthcare-Deal-Trends-in-Latin-America-2008---2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012

Summary

"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012" report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.

The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.

Highlights

Key Questions Answered

- How are the main deal categories faring among top countries in the Latin America region over the past five years?
- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?
- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?
- What strategies are the most successful companies pursuing to gain and maintain their market leading position?
- Which are the key companies that are potential targets of acquisitions?

Scope

- Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
- Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
- Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
- Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
- Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
- Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
- Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.

Reasons to buy

- Understand the primary drivers behind major deal initiatives in the LATAM region.
- Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Report Scope 14
2.1.1 Key Questions Answered 14
2.1.2 Key Benefits 15
2.1.3 Upcoming Related Reports 15
3 Historical Dealmaking Trends 16
3.1 Overview 16
3.2 Leading Deal Drivers 17
3.2.1 Dampening Global Pharmaceutical Markets 17
3.2.2 Intellectual Property Issues and Rising Competition 18
3.2.3 Universal Healthcare Access, Primary Healthcare, and Health Insurance 19
3.2.4 Increasing Consolidation 20
3.3 Overall Deals in Review 21
3.3.1 Review by Deal Type 21
4 Regional Country Profiles 28
4.1 Brazil 28
4.1.1 Overview 28
4.1.2 Top Deals by Value and Volume 29
4.1.3 Market Dynamics 31
4.2 Mexico 34
4.2.1 Overview 34
4.2.2 Top Deals by Value and Volume 35
4.2.3 Market Dynamics 37
4.3 Argentina 41
4.3.1 Overview 41
4.3.2 Top Deals by Value and Volume 42
4.3.3 Market Dynamics 44
4.4 Venezuela 48
4.4.1 Overview 48
4.4.2 Top Deals by Value and Volume 49
4.4.3 Market Dynamics 51
5 Mergers and Acquisitions 55
5.1 Overview 55
5.2 Case Studies 57
5.2.1 UnitedHealth Group Acquires Amil Participações 57
5.2.2 Hypermarcas Acquires Mantecorp Indústria Química e Farmacêutica 59
5.2.3 Hypermarcas Acquires Laboratório Neo Química 60
5.2.4 Acquisition of Lafrancol (Colombia) by Recalcine (Chile) 61
5.2.5 Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
6 Licensing Agreements 64
6.1 Overview 64
6.2 Case Studies 66
6.2.1 FBM Indústria Farmacêutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals 66
6.2.2 FAES Farma and Pfizer Expand Bilastine License Agreement 67
6.2.3 CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
6.2.4 Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
6.2.5 Oxford Nutrascience Enters into Licensing Agreement with Aché Laboratórios 71
7 Collaborations and Partnerships 73
7.1 Overview 73
7.2 Case Studies 75
7.2.1 Pfizer Enters into an Agreement with Laboratório Teuto Brasileiro 75
7.2.2 Avesthagen Forms a Joint Venture with Uxmal 77
7.2.3 Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment 78
7.2.4 Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines 80
7.2.5 Aché , Uniao Química Farmacêutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
8 Deal Strategy of Major LATAM Companies 83
8.1 Amil Participações S.A. 83
8.1.1 Recent Deals: M&As, Licensing, and Partnerships 83
8.1.2 Overall Deal Strategy 84
8.2 Hypermarcas 85
8.2.1 Recent Deals: M&As, Licensing, and Partnerships 85
8.2.2 Overall Deals Strategy 86
8.3 Grupo Casa Saba 87
8.3.1 Recent Deals: M&As, Licensing, and Partnerships 87
8.3.2 Overall Deals Strategy 87
8.4 Genomma Lab Internacional 88
8.4.1 Recent Deals: M&As, Licensing, and Partnerships 88
8.4.2 Overall Deals Strategy 88
8.5 CFR Pharmaceuticals 89
8.5.1 Recent Deals: M&As, Licensing, and Partnerships 89
8.5.2 Overall Deals Strategy 90
9 Future Outlook 91
9.1 Overview 91
9.2 Deal-Making Trends 91
9.2.1 Mergers and Acquisitions 91
9.2.2 Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth 93
9.2.3 Market Access Challenges will Impact Deal Activity 93
10 Appendix 95
10.1 Bibliography 95
10.2 Abbreviations 97
10.3 About the Author 100
10.3.1 Industry Analyst 100
10.4 Director of Healthcare Industry Dynamics 100
10.5 Global Head of Healthcare 101
10.6 About the Industry Dynamics Team 101
10.7 About GlobalData 101
10.8 Disclaimer 102

1.1 List of Tables

Table 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012 29
Table 2: Market Share Split of Pharma Firms in Brazil 33
Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012 35
Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020 38
Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise 39
Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise 40
Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012 42
Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise 46
Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012 49
Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012 56
Table 13: UnitedHealth Acquires Amil Participações 57
Table 14: Hypermarcas Acquires Mantecorp 59
Table 15: Hypermarcas Acquires Laboratório Neo Química Comércio e Indústria 60
Table 16: Recalcine Acquires Lafrancol 61
Table 17: Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
Table 18: Major Licensing Deals, LATAM Region, 2008-2012 64
Table 19: FBM Farma Indústria Farmacêutica Licenses Zertane from Ampio Pharmaceuticals 66
Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine 67
Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratórios 71
Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012 74
Table 25: Pfizer Enters Into An Agreement With Laboratório Teuto Brasileiro 75
Table 26: Avesthagen Enters into Agreement with Uxmal 77
Table 27: Baxter International Enters Into Agreement With Hemobras 78
Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture 80
Table 29: Aché , Uniao Química Farmacêutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
Table 30: Amil Participações ' Recent Deals Activity 83
Table 31: Hypermarcas' Recent Deals Activity 85
Table 32: Grupo Casa Saba's Recent Deals Activity 87
Table 33: Genomma Lab Internacional's Recent Deals Activity 88
Table 34: CFR Pharmaceuticals' Recent Deals Activity 89

List of Figures

Figure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012 17
Figure 2: Research and Development Spending of PhRMA Members, 2005-2012 18
Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012 22
Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012 23
Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012 24
Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012 25
Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012 26
Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012 27
Figure 9: Trends in Deal Volume in Brazil, 2008-2012 30
Figure 10: Volume of Deal Types in Brazil, 2008-2012 31
Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020 32
Figure 12: Trends in Deal Volume in Mexico, 2008-2012 36
Figure 13: Volume of Deal Types in Mexico, 2008-2012 37
Figure 14: Trend in Market Forecast in Mexico, 2011-2020 38
Figure 15: Trends in Deal Volume in Argentina, 2008-2012 43
Figure 16: Volume of Deal Types in Argentina, 2008-2012 44
Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Figure 18: Trends in Deal Volume in Venezuela, 2009-2012 50
Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012 50
Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012 57
Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012 65

To order this report: PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
http://www.reportlinker.com/p02013603/PharmaSphere-Pharmaceutical-and-Healthcare-Deal-Trends-in-Latin-America-2008---2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
The Internet giants are fully embracing AI. All the services they offer to their customers are aimed at drawing a map of the world with the data they get. The AIs from these companies are used to build disruptive approaches that cannot be used by established enterprises, which are threatened by these disruptions. However, most leaders underestimate the effect this will have on their businesses. In his session at 21st Cloud Expo, Rene Buest, Director Market Research & Technology Evangelism at Ara...
"We are a monitoring company. We work with Salesforce, BBC, and quite a few other big logos. We basically provide monitoring for them, structure for their cloud services and we fit into the DevOps world" explained David Gildeh, Co-founder and CEO of Outlyer, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, paneli...
"When we talk about cloud without compromise what we're talking about is that when people think about 'I need the flexibility of the cloud' - it's the ability to create applications and run them in a cloud environment that's far more flexible,” explained Matthew Finnie, CTO of Interoute, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Join us at Cloud Expo June 6-8 to find out how to securely connect your cloud app to any cloud or on-premises data source – without complex firewall changes. More users are demanding access to on-premises data from their cloud applications. It’s no longer a “nice-to-have” but an important differentiator that drives competitive advantages. It’s the new “must have” in the hybrid era. Users want capabilities that give them a unified view of the data to get closer to customers and grow business. The...
Cloud promises the agility required by today’s digital businesses. As organizations adopt cloud based infrastructures and services, their IT resources become increasingly dynamic and hybrid in nature. Managing these require modern IT operations and tools. In his session at 20th Cloud Expo, Raj Sundaram, Senior Principal Product Manager at CA Technologies, will discuss how to modernize your IT operations in order to proactively manage your hybrid cloud and IT environments. He will be sharing bes...
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists loo...
"Loom is applying artificial intelligence and machine learning into the entire log analysis process, from start to finish and at the end you will get a human touch,” explained Sabo Taylor Diab, Vice President, Marketing at Loom Systems, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, highlighted the current challenges of these transformative technologies and shared strategies for preparing your organization for these changes. This “view from the top” outlined the latest trends and developments i...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.